Argenica Therapeutics Ltd (ASX:AGN, OTC:OTCMKTS: AGNTF) CEO and managing director, Dr Liz Dallimore talked with Proactive's Stephen Gunnion about the company’s ongoing clinical trial of its lead drug candidate, ARG-007, targeting acute ischemic stroke. This trial, now over halfway completed, focuses on patients with large vessel occlusion strokes. ARG-007 aims to protect brain cells in stroke patients by preventing cellular death post-stroke, offering hope for conditions that currently lack protective treatments. Dallimore shared that Argenica has successfully recruited and dosed 58 patients out of a targeted 92, with expectations to complete dosing by mid-next year. “The fact that we didn’t see any serious adverse events that could have been possibly related to the drug is a massive tick of approval,” Dallimore noted, marking a significant milestone validated by the Data Safety Monitoring Board. The broader potential for ARG-007 extends beyond stroke, addressing an estimated $18 billion market across other brain injuries, including traumatic brain injury and neurodegenerative diseases. With topline results anticipated around this time next year, the company remains optimistic about the drug's impact, especially regarding its primary safety endpoint. For more in-depth updates on Argenica Therapeutics’ pioneering work in brain injury treatments, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and enable notifications for future insights. #ArgenicaTherapeutics #StrokeTreatment #ARG007 #ClinicalTrials #BrainInjury #Neurology #HealthcareInnovation #DrLizDallimore #PharmaNews #Biotechnology #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews